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INTRODUCTION
Hepatitis B virus (HBV) infection remains a global health problem, 
with more than 350 million people chronically infected with 
the virus worldwide.(1) Hepatitis B vaccines are effective in 
preventing HBV infection. In 2009, the World Health Organization 
(WHO) reported that up to 177 countries had included 
hepatitis B vaccination into their national infant immunisation 
programmes.(2) Various studies have shown that immunisation 
in infancy provides adequate protection against HBV infection, 
which lasts even till school-going age.(3) However, studies have 
also found that not every recipient of the vaccine produces 
adequate protective levels of the antibody after completion of 
primary immunisation.(4)
 In Malaysia, universal hepatitis B vaccination of all newborn 
infants has been implemented since 1989. However, to the 
authors’ knowledge, only one industry-sponsored study has 
ever assessed the seroprotective anti-hepatitis B antibody 
(anti-HBs) levels in a setting where hepatitis B vaccines were 
given in combination with other childhood vaccines.(5) The 
efficacy of the universal hepatitis B vaccination programme has 
never been assessed in a community setting in Malaysia. The 
aim of the present study was to assess the immune response 
of newborns who received the three-shot hepatitis B vaccine 
at community child health clinics in Malaysia, by measuring 
their anti-HBs levels after immunisation at approximately one 
year of age.
METHODS
The present study was conducted among infants who attended 
the child health clinic at Lam Wah Ee Hospital (LWEH), 
a charitable hospital that caters mainly to the lower-to-middle 
income population in Penang, Malaysia. The study was approved 
by the institutional ethics review committee. 
 Consecutive newborn infants delivered at LWEH between 
March 2002 and April 2010 (study period, 8 years 2 months), 
who were managed by a single clinician, were screened for anti-
HBs levels after the completion of their primary immunisation, 
at approximately one year of age. All newborn infants were 
given the three-shot hepatitis B vaccine at birth, one month and 
six months of age. Prior to 2002, the hepatitis B vaccine given 
at LWEH was Hepavax-Gene (Crucell, Leiden, The Netherlands), 
while that given after 2002 was Engerix-B® (GlaxoSmithKline 
Biologicals, Rixensart, Belgium). Infants delivered to mothers 
who were positive for hepatitis B surface antigen (HBsAg) 
were additionally given anti-hepatitis B immunoglobulin 
(Hepabig®; VHB Life Sciences, Mumbai, India) within 24 hours 
of birth.
 Screening for anti-HBs levels was performed at approximately 
one year of age. Adequate protective level of anti-HBs was 
defined as antibody level ≥ 10 IU/L.(6) Screenings for HBsAg and 
anti-HBs were performed using chemiluminescent microparticle 
immunoassay techniques (Abbott Architect ci8200 Analyser; 
Abbott Diagnostics, Abbott Park, IL, USA). 
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RESUlTS
A total of 572 consecutive infants, delivered between March 
2002 and April 2010 at LWEH, who received the three-shot 
hepatitis B vaccine, were screened for immune response to 
hepatitis B vaccination (Table I). Of these, 304 (53.1%) infants 
were male. The ethnicities of the infants were: 283 (49.5%) 
Chinese, 143 (25.0%) Malay, 140 (24.5%) Indian, and 6 (1.0%) 
minor ethnicities. A majority of infants (n = 503, 88.0%) were 
delivered at term (gestational age ≥ 37 completed weeks). 
A total of 426 (74.5%) mothers were HBsAg negative, while 14 
(2.4%) were HBsAg positive. Among women with known HBsAg 
status (n = 440), 14 (3.2%) were HBsAg-positive. The HBV status 
of 132 (23.0%) women was unknown. All 572 infants received 
the first dose of hepatitis B vaccine at birth. However, only 506 
(88.5%) and 551 (96.3%) infants had a record of receiving the 
second and third dose of the vaccine, respectively, at LWEH. 
Screening for anti-HBs was performed at a median age of 
9.3 ± 2.7 (range 6.3–48) months.
 Among the 572 infants, 19 (3.3%) had inadequate antibody 
response – anti-HBs antibody was not detected in 3 (0.5%) 
infants, while antibody levels were < 10 IU/L for another 16 
(2.8%) infants. Among the remaining 553 (96.7%) infants who 
had antibody levels ≥ 10 IU/L, 310 (54.2%) had antibody levels 
> 1,000 IU/L. Factors such as gender, gestational age and 
maternal HBsAg status were not found to significantly affect 
the subsequent anti-HBs antibody levels in infants receiving 
hepatitis B vaccination (Table I). The majority of infants (13/14) 
delivered to HBsAg-positive mothers had adequate antibody 
levels. None of the infants in our group was found to be 
HBsAg-positive.
DISCUSSION
Universal hepatitis B vaccination is known to bring enormous 
benefits to communities where HBV infection is endemic.(1) 
Hepatitis B vaccination has been associated with the elimination 
or reduction of childhood hepatocellular carcinoma,(7) acute 
liver failure(8) and, more recently, virus-associated membranous 
nephropathy.(9) Universal hepatitis B immunisation of newborns 
has been implemented in Malaysia since 1989.(10) Since then, 
there has been a steady decline in the seroprevalence of 
HBsAg – from 2.5% for children born in 1985 (four years before 
universal immunisation) to 0.4% among school children born 
in 1996.(10)
 The results of the present study show that universal hepatitis B 
vaccination of newborns in Malaysia is highly successful. 96.7% 
of the 572 infants immunised in our study were found to have 
adequate levels of anti-HBs at approximately one year of age. 
Furthermore, none of the 14 infants who were born to HBsAg-
positive mothers were found to be HBsAg-positive. Among 
these 14 infants, 13 were found to have adequate levels of 
protective anti-HBs following immunisation. Failure to produce 
detectable antibody levels even after three doses of hepatitis B 
vaccines has been reported in a small minority of patients.(11) 
Researchers have adopted various methods to overcome this 
problem, including administering a fourth dose of vaccine(11) 
or a booster dose at a later age.(3) However, it should be noted 
that the risk of acquiring HBV infection among non-responders 
has been found to be similar to that among those given booster 
vaccines.(3)
 The present study also found that chronic HBV infection 
remains high among Malaysian mothers, with 3.2% of women 
whose HBsAg status was known testing positive for HBsAg. 
This underscores the importance of universal hepatitis B 
vaccination. We expect that the proportion of HBsAg-positive 
women will dramatically decrease as the cohort of Malaysian 
women who received universal hepatitis B vaccination 
(introduced in 1989) enters reproductive age. However, for women 
who had not been immunised, screening at antenatal clinics 
for HBsAg remains an important strategy for reducing vertical 
transmissions.(12)
 One of the potential drawbacks of the present study was the 
lack of information on the status of hepatitis B e antigen (HBeAg) 
among women who were HBsAg positive, as it is well known 
that vertical transmission is more likely to occur among infants 
born to women who are positive for both HBeAg and HBsAg.(12)
 In conclusion, the proportion of Malaysian mothers who 
are positive for HBsAg remains high. Our results suggest that 
universal vaccination of newborns with three doses of hepatitis B 
vaccine in a community clinic setting in Malaysia has proven 
highly successful in preventing the perinatal transmission of 
HBV infection, as well as achieving adequate protective levels of 
anti-HBs in a vast majority of infants.
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Table I. Immune response to hepatitis B vaccination in Malaysian 
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Variable No. of infants (%) p-value
Antibody level  
≥ 10 IU/l (n = 553)
Antibody level  
< 10 IU/l (n = 19)
Gender 0.15
Male 290 (52.4) 14 (73.7)
Female 263 (47.6) 5 (26.3)
Gestational age 0.26
Term 485 (87.7) 18 (94.7)
Preterm 58 (10.5) 1 (5.3)




Positive 13 (2.4) 1 (5.3)
Negative 412 (74.5) 14 (73.7)
Unknown 128 (23.1) 4 (21.1)
HBsAg: hepatitis B surface antigen
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